
Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Published on 07/29/2021

COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

Pathogen and Human Genomics Studies

- Whole-Genome Sequencing of SARS-CoV-2 from Quarantine Hotel Outbreak.
(<https://pubmed.ncbi.nlm.nih.gov/34287141>)

Leong Lex E X et al. Emerging infectious diseases 2021 7 (8) 2219-2221

Hotel quarantine for international travelers has been used to prevent coronavirus disease spread into Australia. A quarantine hotel-associated community outbreak was detected in South Australia. Real-time genomic sequencing enabled rapid confirmation tracking the outbreak to a recently returned traveler and linked 2 cases of infection in travelers at the same facility.

- mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged =16 Years in the United States, February to May 2021

(<https://www.medrxiv.org/content/10.1101/2021.07.20.21260647v1>)

SS Kim et al, MEDRXIV, July 22, 2021

valuations of vaccine effectiveness (VE) are important to monitor as COVID-19 vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or SARS-CoV-2 testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged =16 years, VE of mRNA vaccines against COVID-19 was 91% (95% CI: 83-95) for full vaccination and 75% (95% CI: 55-87) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care.

- Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples. (<https://pubmed.ncbi.nlm.nih.gov/34287620>)

Bates Timothy A et al. JAMA 2021 7

In this study, initial vaccine-elicited neutralizing antibody titers were negatively associated with age, resulting in a diminished ability to neutralize SARS-CoV-2 in vitro. Neutralizing titers against P.1 were reduced across all ages, although the magnitude of the age-dependent difference was smaller.

- New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations (<https://www.medrxiv.org/content/10.1101/2021.07.21.21260624v1>)

F Degenhardt et al, MEDRXIV, July 23, 2021

We describe an extended GWAS meta-analysis of 3,260 COVID-19 patients with respiratory failure and 12,483 population controls from Italy, Spain, Norway and Germany, as well as hypothesis-driven targeted analysis of the human leukocyte antigen (HLA) region and chromosome Y haplotypes. We include detailed stratified analyses based on age, sex and disease severity. In addition to already established risk loci, our data identify and replicate two genome-wide significant loci at 17q21.31 and 19q13.33 associated with severe COVID-19 with respiratory failure.

- BNT162b2 Vaccination efficacy is marginally affected by the SARS-CoV-2 B.1.351 variant in fully vaccinated individuals. (<https://www.medrxiv.org/content/10.1101/2021.07.20.21260833v1>)

A Huppert et al, MEDRXIV, July 23, 2021

We used logistic regression, with variant type as the dependent variable, vaccination status as the main explanatory variable, controlling for age, sex, subpopulation, place of residence and time of sample, to estimate the odds ratio for a vaccinated case to have the B. 1.351 versus the B.1.1.7 variant, within vaccinated and unvaccinated persons who tested positive. Findings There were 19 cases of B.1.351 variant (3.2%) among those vaccinated more than 14 days before the positive sample and 88 (3.5%) among the unvaccinated. The estimated odds ratio was 1.29 [95% CI: 0.66-2.50].

- Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence

(<https://pubmed.ncbi.nlm.nih.gov/34301854/>)

Kraemer MU, et al. Science. 2021 Jul 22;eabj0113.

We investigate the spatial invasion dynamics of lineage B.1.1.7 by jointly analyzing UK human mobility, virus genomes, and community-based PCR data. We identify a multi-stage spatial invasion process in which early B.1.1.7 growth rates were associated with mobility and asymmetric lineage export from a dominant source location....Our findings show that careful accounting of the behavioral and epidemiological context within which variants of concern emerge is necessary to interpret correctly their observed relative growth rates.

- Shorter leukocyte telomere length is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank ([https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964\(21\)00278-4/fulltext](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00278-4/fulltext))

Q Wang et al, Ebiomedicine, July 2021

Findings Of 6775 participants in UKB who tested positive for infection with SARS-CoV-2 in the community, there were 914 (13.5%) with adverse COVID-19 outcomes. The odds ratio (OR) for adverse COVID-19 outcomes was 1.17 (95% CI 1.05–1.30; P = 0.004) per 1-SD shorter usual LTL, after adjustment for age, sex and ethnicity.

- Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

(<https://www.nature.com/articles/s41591-021-01464-w>)

T Schmidt et al, Nature Medicine, July 26, 2021

In this observational study we show that, in healthy adult individuals (n=?96), the heterologous vaccine regimen induced spike-specific IgG, neutralizing antibodies and spike-specific CD4 T?cells, the levels of which which were significantly higher than after homologous vector vaccine boost (n=?55) and higher or comparable in magnitude to homologous mRNA vaccine regimens (n=?62). Moreover, spike-specific CD8 T?cell levels after heterologous vaccination were significantly higher than after both homologous regimens.

- Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. (<https://pubmed.ncbi.nlm.nih.gov/34309623>)

Krantz Matthew S et al. JAMA internal medicine 2021 7

This multisite US study supports the safety of Pfizer-BioNTech or Moderna vaccine second dose administration in patients who report immediate and potentially allergic reactions after the first dose. Although mild symptoms were reported in 20% of patients with second dose administration, all patients who received a second dose safely completed their vaccination series and could use mRNA COVID-19 vaccines in the future when indicated.

- No evidence that vitamin D is able to prevent or affect the severity of COVID-19 in individuals with European ancestry: a Mendelian randomisation study of open data.

(<https://pubmed.ncbi.nlm.nih.gov/34308111>)

Amin Hasnat A et al. BMJ nutrition, prevention & health 2021 7 (1) 42-48

We used two-sample Mendelian randomisation (MR) to assess the causal effect of vitamin D levels on SARS-CoV-2 infection risk and COVID-19 severity using publicly available data. We also carried out a genome-wide association analysis (GWA) of vitamin D deficiency in the UK Biobank. we found no evidence that vitamin D is protective against SARS-CoV-2 infection or COVID-19 severity.

- Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence.

(<https://pubmed.ncbi.nlm.nih.gov/34301854>)

Kraemer Moritz U G et al. Science (New York, N.Y.) 2021 7

We investigate the spatial invasion dynamics of lineage B.1.1.7 by jointly analyzing UK human mobility, virus genomes, and community-based PCR data. We identify a multi-stage spatial invasion process in which early B.1.1.7 growth rates were associated with mobility and asymmetric lineage export from a dominant source location, enhancing the effects of B.1.1.7's increased intrinsic transmissibility. We

further explore how B.1.1.7 spread was shaped by non-pharmaceutical interventions and spatial variation in previous attack rates. Our findings show that careful accounting of the behavioral and epidemiological context within which variants of concern emerge is necessary to interpret correctly their observed relative growth rates.

- Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences. (<https://pubmed.ncbi.nlm.nih.gov/34303698>)

Olsen Randall J et al. The American journal of pathology 2021 7

Prevalence of the B.1.1.7 (Alpha) variant increased rapidly and caused 63%-90% of new cases in the latter half of May. Eleven B.1.1.7 genomes had an E484K replacement in spike protein, a change also identified in other SARS-CoV-2 lineages. Compared with non-B.1.1.7-infected patients, individuals with B.1.1.7 had a significantly lower cycle threshold (a proxy for higher virus load) and significantly higher hospitalization rate. Other variants (e.g., B.1.429 and B.1.427 (Epsilon), P.1 (Gamma), P.2 (Zeta), and R.1) also increased rapidly, although the magnitude was less than B.1.1.7. We identified 22 patients infected with B.1.617.1 (Kappa) or B.1.617.2 (Delta) variants; these patients had a high rate of hospitalization. Breakthrough cases (n=207) in fully vaccinated patients were caused by a heterogeneous array of virus genotypes, including many that are not currently designated variants of interest or concern

- SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts. (<https://pubmed.ncbi.nlm.nih.gov/34297786>)
Tasakis Rafail Nikolaos et al. PloS one 2021 7 (7) e0255169

Our study explores evolution of SARS-CoV-2 in a representative cohort of sequences covering the entire genome in the United States, through all of 2020 and early 2021. Strikingly, we detected many accumulating Single Nucleotide Variations (SNVs) encoding amino acid changes in the SARS-CoV-2 genome, with a pattern indicative of RNA editing enzymes as major mutators of SARS-CoV-2 genomes. We report three major variants through October of 2020. These revealed 14 key mutations that were found in various combinations among 14 distinct predominant signatures. These signatures likely represent evolutionary lineages of SARS-CoV-2 in the U.S. and reveal clues to its evolution such as a mutational burst in the summer of 2020 likely leading to a homegrown new variant, and a trend towards higher mutational load among viral isolates.

- Surveillance Data Shows White-Tailed Deer Exposed to SARS-CoV-2
(<https://content.govdelivery.com/accounts/USDAAPHIS/bulletins/2ea5c07>)
USDA Animal and Plant Health Inspection Service, Jul 28, 2021.

It is important to note that this surveillance was designed to determine exposure of deer to SARS-CoV-2 in their natural environment. It was not designed to determine whether the deer were replicating and shedding SARS-CoV-2. APHIS supports a One Health approach to addressing animal diseases, including SARS-CoV-2. Widespread human infections with SARS-CoV-2 combined with human-wildlife interactions create the potential for spillover between people and animals. Studying the susceptibility

of certain mammals, such as deer, to SARS-CoV-2 helps to identify species that may serve as reservoirs or hosts for the virus, as well as understand the origin of the virus, and predict its impacts on wildlife and the risks of cross-species transmission.

Non-Genomics Precision Health Studies

- Whole-Genome Sequencing of SARS-CoV-2 from Quarantine Hotel Outbreak.
(<https://pubmed.ncbi.nlm.nih.gov/34287141>)

Leong Lex E X et al. *Emerging infectious diseases* 2021 7 (8) 2219-2221

Hotel quarantine for international travelers has been used to prevent coronavirus disease spread into Australia. A quarantine hotel-associated community outbreak was detected in South Australia. Real-time genomic sequencing enabled rapid confirmation tracking the outbreak to a recently returned traveler and linked 2 cases of infection in travelers at the same facility.

- mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged =16 Years in the United States, February to May 2021

(<https://www.medrxiv.org/content/10.1101/2021.07.20.21260647v1>)

SS Kim et al, *MEDRXIV*, July 22, 2021

valuations of vaccine effectiveness (VE) are important to monitor as COVID-19 vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or SARS-CoV-2 testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged =16 years, VE of mRNA vaccines against COVID-19 was 91% (95% CI: 83-95) for full vaccination and 75% (95% CI: 55-87) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care.

- Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples.
(<https://pubmed.ncbi.nlm.nih.gov/34287620>)

Bates Timothy A et al. *JAMA* 2021 7

In this study, initial vaccine-elicited neutralizing antibody titers were negatively associated with age, resulting in a diminished ability to neutralize SARS-CoV-2 in vitro. Neutralizing titers against P.1 were reduced across all ages, although the magnitude of the age-dependent difference was smaller.

- New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations
(<https://www.medrxiv.org/content/10.1101/2021.07.21.21260624v1>)

F Degenhardt et al, *MEDRXIV*, July 23, 2021

We describe an extended GWAS meta-analysis of 3,260 COVID-19 patients with respiratory failure and 12,483 population controls from Italy, Spain, Norway and Germany, as well as hypothesis-driven

targeted analysis of the human leukocyte antigen (HLA) region and chromosome Y haplotypes. We include detailed stratified analyses based on age, sex and disease severity. In addition to already established risk loci, our data identify and replicate two genome-wide significant loci at 17q21.31 and 19q13.33 associated with severe COVID-19 with respiratory failure.

- BNT162b2 Vaccination efficacy is marginally affected by the SARS-CoV-2 B.1.351 variant in fully vaccinated individuals. (<https://www.medrxiv.org/content/10.1101/2021.07.20.21260833v1>)
A Huppert et al, MEDRXIV, July 23, 2021

We used logistic regression, with variant type as the dependent variable, vaccination status as the main explanatory variable, controlling for age, sex, subpopulation, place of residence and time of sample, to estimate the odds ratio for a vaccinated case to have the B. 1.351 versus the B.1.1.7 variant, within vaccinated and unvaccinated persons who tested positive. Findings There were 19 cases of B.1.351 variant (3.2%) among those vaccinated more than 14 days before the positive sample and 88 (3.5%) among the unvaccinated. The estimated odds ratio was 1.29 [95% CI: 0.66-2.50].

- Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence (<https://pubmed.ncbi.nlm.nih.gov/34301854/>)
Kraemer MU, et al. Science. 2021 Jul 22;eabj0113.

We investigate the spatial invasion dynamics of lineage B.1.1.7 by jointly analyzing UK human mobility, virus genomes, and community-based PCR data. We identify a multi-stage spatial invasion process in which early B.1.1.7 growth rates were associated with mobility and asymmetric lineage export from a dominant source location....Our findings show that careful accounting of the behavioral and epidemiological context within which variants of concern emerge is necessary to interpret correctly their observed relative growth rates.

- Shorter leukocyte telomere length is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank ([https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964\(21\)00278-4/fulltext](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00278-4/fulltext))
Q Wang et al, Ebiomedicine, July 2021

Findings Of 6775 participants in UKB who tested positive for infection with SARS-CoV-2 in the community, there were 914 (13.5%) with adverse COVID-19 outcomes. The odds ratio (OR) for adverse COVID-19 outcomes was 1.17 (95% CI 1.05–1.30; P = 0.004) per 1-SD shorter usual LTL, after adjustment for age, sex and ethnicity.

- Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination (<https://www.nature.com/articles/s41591-021-01464-w>)
T Schmidt et al, Nature Medicine, July 26, 2021

In this observational study we show that, in healthy adult individuals (n=?96), the heterologous vaccine regimen induced spike-specific IgG, neutralizing antibodies and spike-specific CD4 T?cells, the levels of which which were significantly higher than after homologous vector vaccine boost (n=?55) and higher or comparable in magnitude to homologous mRNA vaccine regimens (n=?62). Moreover,

spike-specific CD8 T?cell levels after heterologous vaccination were significantly higher than after both homologous regimens.

- Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. (<https://pubmed.ncbi.nlm.nih.gov/34309623>)
Krantz Matthew S et al. JAMA internal medicine 2021 7

This multisite US study supports the safety of Pfizer-BioNTech or Moderna vaccine second dose administration in patients who report immediate and potentially allergic reactions after the first dose. Although mild symptoms were reported in 20% of patients with second dose administration, all patients who received a second dose safely completed their vaccination series and could use mRNA COVID-19 vaccines in the future when indicated.

- No evidence that vitamin D is able to prevent or affect the severity of COVID-19 in individuals with European ancestry: a Mendelian randomisation study of open data.
(<https://pubmed.ncbi.nlm.nih.gov/34308111>)
Amin Hasnat A et al. BMJ nutrition, prevention & health 2021 7 (1) 42-48

We used two-sample Mendelian randomisation (MR) to assess the causal effect of vitamin D levels on SARS-CoV-2 infection risk and COVID-19 severity using publicly available data. We also carried out a genome-wide association analysis (GWA) of vitamin D deficiency in the UK Biobank. we found no evidence that vitamin D is protective against SARS-CoV-2 infection or COVID-19 severity.

- Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence.
(<https://pubmed.ncbi.nlm.nih.gov/34301854>)
Kraemer Moritz U G et al. Science (New York, N.Y.) 2021 7

We investigate the spatial invasion dynamics of lineage B.1.1.7 by jointly analyzing UK human mobility, virus genomes, and community-based PCR data. We identify a multi-stage spatial invasion process in which early B.1.1.7 growth rates were associated with mobility and asymmetric lineage export from a dominant source location, enhancing the effects of B.1.1.7's increased intrinsic transmissibility. We further explore how B.1.1.7 spread was shaped by non-pharmaceutical interventions and spatial variation in previous attack rates. Our findings show that careful accounting of the behavioral and epidemiological context within which variants of concern emerge is necessary to interpret correctly their observed relative growth rates.

- Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences. (<https://pubmed.ncbi.nlm.nih.gov/34303698>)
Olsen Randall J et al. The American journal of pathology 2021 7

Prevalence of the B.1.1.7 (Alpha) variant increased rapidly and caused 63%-90% of new cases in the latter half of May. Eleven B.1.1.7 genomes had an E484K replacement in spike protein, a change also identified in other SARS-CoV-2 lineages. Compared with non-B.1.1.7-infected patients, individuals with B.1.1.7 had a significantly lower cycle threshold (a proxy for higher virus load) and significantly

higher hospitalization rate. Other variants (e.g., B.1.429 and B.1.427 (Epsilon), P.1 (Gamma), P.2 (Zeta), and R.1) also increased rapidly, although the magnitude was less than B.1.1.7. We identified 22 patients infected with B.1.617.1 (Kappa) or B.1.617.2 (Delta) variants; these patients had a high rate of hospitalization. Breakthrough cases (n=207) in fully vaccinated patients were caused by a heterogeneous array of virus genotypes, including many that are not currently designated variants of interest or concern

- SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts. (<https://pubmed.ncbi.nlm.nih.gov/34297786>)
Tasakis Rafail Nikolaos et al. PLoS one 2021 7 (7) e0255169

Our study explores evolution of SARS-CoV-2 in a representative cohort of sequences covering the entire genome in the United States, through all of 2020 and early 2021. Strikingly, we detected many accumulating Single Nucleotide Variations (SNVs) encoding amino acid changes in the SARS-CoV-2 genome, with a pattern indicative of RNA editing enzymes as major mutators of SARS-CoV-2 genomes. We report three major variants through October of 2020. These revealed 14 key mutations that were found in various combinations among 14 distinct predominant signatures. These signatures likely represent evolutionary lineages of SARS-CoV-2 in the U.S. and reveal clues to its evolution such as a mutational burst in the summer of 2020 likely leading to a homegrown new variant, and a trend towards higher mutational load among viral isolates.

- Surveillance Data Shows White-Tailed Deer Exposed to SARS-CoV-2
(<https://content.govdelivery.com/accounts/USDAAPHIS/bulletins/2ea5c07>)
USDA Animal and Plant Health Inspection Service, Jul 28, 2021.

It is important to note that this surveillance was designed to determine exposure of deer to SARS-CoV-2 in their natural environment. It was not designed to determine whether the deer were replicating and shedding SARS-CoV-2. APHIS supports a One Health approach to addressing animal diseases, including SARS-CoV-2. Widespread human infections with SARS-CoV-2 combined with human-wildlife interactions create the potential for spillover between people and animals. Studying the susceptibility of certain mammals, such as deer, to SARS-CoV-2 helps to identify species that may serve as reservoirs or hosts for the virus, as well as understand the origin of the virus, and predict its impacts on wildlife and the risks of cross-species transmission.

News, Reviews and Commentaries

- Whole-Genome Sequencing of SARS-CoV-2 from Quarantine Hotel Outbreak.
(<https://pubmed.ncbi.nlm.nih.gov/34287141>)
Leong Lex E X et al. Emerging infectious diseases 2021 7 (8) 2219-2221

Hotel quarantine for international travelers has been used to prevent coronavirus disease spread into Australia. A quarantine hotel-associated community outbreak was detected in South Australia. Real-

time genomic sequencing enabled rapid confirmation tracking the outbreak to a recently returned traveler and linked 2 cases of infection in travelers at the same facility.

- mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥ 16 Years in the United States, February to May 2021

(<https://www.medrxiv.org/content/10.1101/2021.07.20.21260647v1>)

SS Kim et al, MEDRXIV, July 22, 2021

valuations of vaccine effectiveness (VE) are important to monitor as COVID-19 vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or SARS-CoV-2 testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged ≥ 16 years, VE of mRNA vaccines against COVID-19 was 91% (95% CI: 83-95) for full vaccination and 75% (95% CI: 55-87) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care.

- Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples.

(<https://pubmed.ncbi.nlm.nih.gov/34287620>)

Bates Timothy A et al. JAMA 2021 7

In this study, initial vaccine-elicited neutralizing antibody titers were negatively associated with age, resulting in a diminished ability to neutralize SARS-CoV-2 in vitro. Neutralizing titers against P.1 were reduced across all ages, although the magnitude of the age-dependent difference was smaller.

- New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations

(<https://www.medrxiv.org/content/10.1101/2021.07.21.21260624v1>)

F Degenhardt et al, MEDRXIV, July 23, 2021

We describe an extended GWAS meta-analysis of 3,260 COVID-19 patients with respiratory failure and 12,483 population controls from Italy, Spain, Norway and Germany, as well as hypothesis-driven targeted analysis of the human leukocyte antigen (HLA) region and chromosome Y haplotypes. We include detailed stratified analyses based on age, sex and disease severity. In addition to already established risk loci, our data identify and replicate two genome-wide significant loci at 17q21.31 and 19q13.33 associated with severe COVID-19 with respiratory failure.

- BNT162b2 Vaccination efficacy is marginally affected by the SARS-CoV-2 B.1.351 variant in fully vaccinated individuals. (<https://www.medrxiv.org/content/10.1101/2021.07.20.21260833v1>)

A Huppert et al, MEDRXIV, July 23, 2021

We used logistic regression, with variant type as the dependent variable, vaccination status as the main explanatory variable, controlling for age, sex, subpopulation, place of residence and time of sample, to estimate the odds ratio for a vaccinated case to have the B. 1.351 versus the B.1.1.7 variant, within vaccinated and unvaccinated persons who tested positive. Findings There were 19 cases of

B.1.351 variant (3.2%) among those vaccinated more than 14 days before the positive sample and 88 (3.5%) among the unvaccinated. The estimated odds ratio was 1.29 [95% CI: 0.66-2.50].

- Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence

(<https://pubmed.ncbi.nlm.nih.gov/34301854/>)

Kraemer MU, et al. Science. 2021 Jul 22;eabj0113.

We investigate the spatial invasion dynamics of lineage B.1.1.7 by jointly analyzing UK human mobility, virus genomes, and community-based PCR data. We identify a multi-stage spatial invasion process in which early B.1.1.7 growth rates were associated with mobility and asymmetric lineage export from a dominant source location....Our findings show that careful accounting of the behavioral and epidemiological context within which variants of concern emerge is necessary to interpret correctly their observed relative growth rates.

- Shorter leukocyte telomere length is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank

([https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964\(21\)00278-4/fulltext](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00278-4/fulltext))

Q Wang et al, Ebiomedicine, July 2021

Findings Of 6775 participants in UKB who tested positive for infection with SARS-CoV-2 in the community, there were 914 (13.5%) with adverse COVID-19 outcomes. The odds ratio (OR) for adverse COVID-19 outcomes was 1.17 (95% CI 1.05–1.30; P = 0.004) per 1-SD shorter usual LTL, after adjustment for age, sex and ethnicity.

- Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

(<https://www.nature.com/articles/s41591-021-01464-w>)

T Schmidt et al, Nature Medicine, July 26, 2021

In this observational study we show that, in healthy adult individuals (n=?96), the heterologous vaccine regimen induced spike-specific IgG, neutralizing antibodies and spike-specific CD4 T?cells, the levels of which which were significantly higher than after homologous vector vaccine boost (n=?55) and higher or comparable in magnitude to homologous mRNA vaccine regimens (n=?62). Moreover, spike-specific CD8 T?cell levels after heterologous vaccination were significantly higher than after both homologous regimens.

- Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. (<https://pubmed.ncbi.nlm.nih.gov/34309623>)

Krantz Matthew S et al. JAMA internal medicine 2021 7

This multisite US study supports the safety of Pfizer-BioNTech or Moderna vaccine second dose administration in patients who report immediate and potentially allergic reactions after the first dose. Although mild symptoms were reported in 20% of patients with second dose administration, all patients who received a second dose safely completed their vaccination series and could use mRNA COVID-19 vaccines in the future when indicated.

- No evidence that vitamin D is able to prevent or affect the severity of COVID-19 in individuals with European ancestry: a Mendelian randomisation study of open data.

(<https://pubmed.ncbi.nlm.nih.gov/34308111>)

Amin Hasnat A et al. *BMJ nutrition, prevention & health* 2021 7 (1) 42-48

We used two-sample Mendelian randomisation (MR) to assess the causal effect of vitamin D levels on SARS-CoV-2 infection risk and COVID-19 severity using publicly available data. We also carried out a genome-wide association analysis (GWA) of vitamin D deficiency in the UK Biobank. We found no evidence that vitamin D is protective against SARS-CoV-2 infection or COVID-19 severity.

- Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence.

(<https://pubmed.ncbi.nlm.nih.gov/34301854>)

Kraemer Moritz U G et al. *Science* (New York, N.Y.) 2021 7

We investigate the spatial invasion dynamics of lineage B.1.1.7 by jointly analyzing UK human mobility, virus genomes, and community-based PCR data. We identify a multi-stage spatial invasion process in which early B.1.1.7 growth rates were associated with mobility and asymmetric lineage export from a dominant source location, enhancing the effects of B.1.1.7's increased intrinsic transmissibility. We further explore how B.1.1.7 spread was shaped by non-pharmaceutical interventions and spatial variation in previous attack rates. Our findings show that careful accounting of the behavioral and epidemiological context within which variants of concern emerge is necessary to interpret correctly their observed relative growth rates.

- Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences. (<https://pubmed.ncbi.nlm.nih.gov/34303698>)

Olsen Randall J et al. *The American journal of pathology* 2021 7

Prevalence of the B.1.1.7 (Alpha) variant increased rapidly and caused 63%-90% of new cases in the latter half of May. Eleven B.1.1.7 genomes had an E484K replacement in spike protein, a change also identified in other SARS-CoV-2 lineages. Compared with non-B.1.1.7-infected patients, individuals with B.1.1.7 had a significantly lower cycle threshold (a proxy for higher virus load) and significantly higher hospitalization rate. Other variants (e.g., B.1.429 and B.1.427 (Epsilon), P.1 (Gamma), P.2 (Zeta), and R.1) also increased rapidly, although the magnitude was less than B.1.1.7. We identified 22 patients infected with B.1.617.1 (Kappa) or B.1.617.2 (Delta) variants; these patients had a high rate of hospitalization. Breakthrough cases (n=207) in fully vaccinated patients were caused by a heterogeneous array of virus genotypes, including many that are not currently designated variants of interest or concern

- SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts. (<https://pubmed.ncbi.nlm.nih.gov/34297786>)

Tasakis Rafail Nikolaos et al. *PLoS one* 2021 7 (7) e0255169

Our study explores evolution of SARS-CoV-2 in a representative cohort of sequences covering the entire genome in the United States, through all of 2020 and early 2021. Strikingly, we detected many

accumulating Single Nucleotide Variations (SNVs) encoding amino acid changes in the SARS-CoV-2 genome, with a pattern indicative of RNA editing enzymes as major mutators of SARS-CoV-2 genomes. We report three major variants through October of 2020. These revealed 14 key mutations that were found in various combinations among 14 distinct predominant signatures. These signatures likely represent evolutionary lineages of SARS-CoV-2 in the U.S. and reveal clues to its evolution such as a mutational burst in the summer of 2020 likely leading to a homegrown new variant, and a trend towards higher mutational load among viral isolates.

- Surveillance Data Shows White-Tailed Deer Exposed to SARS-CoV-2 (<https://content.govdelivery.com/accounts/USDAAPHIS/bulletins/2ea5c07>)
USDA Animal and Plant Health Inspection Service, Jul 28, 2021.

It is important to note that this surveillance was designed to determine exposure of deer to SARS-CoV-2 in their natural environment. It was not designed to determine whether the deer were replicating and shedding SARS-CoV-2. APHIS supports a One Health approach to addressing animal diseases, including SARS-CoV-2. Widespread human infections with SARS-CoV-2 combined with human-wildlife interactions create the potential for spillover between people and animals. Studying the susceptibility of certain mammals, such as deer, to SARS-CoV-2 helps to identify species that may serve as reservoirs or hosts for the virus, as well as understand the origin of the virus, and predict its impacts on wildlife and the risks of cross-species transmission.

Disclaimer: Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

Page last reviewed: Oct 1, 2020

Page last updated: Jul 31, 2021

Content source: Office of Genomics and Precision Public Health (<http://www.cdc.gov/genomics/>), CDC Office of Science (<https://www.cdc.gov/od/science/index.htm>)